Skip to main content

Advertisement

Table 1 Percentage of patients achieving normalization1 of C-reactive protein levels and serum amyloid A protein levels

From: Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

Variable Canakinumab 10 mg N= 28 Canakinumab 25 mg N= 29 Canakinumab 50 mg N= 28 Canakinumab 90 mg N= 29 Canakinumab 150 mg N= 27 Triamcinolone acetonide 40 mg N= 56
CRP       
Baseline 4 (14.3) 8 (27.6) 6 (21.4) 6 (20.7) 5 (18.5) 12 (21.4)
3 days post-dose 6 (22.2) 13 (46.4) 9 (34.6) 9 (32.1) 11 (44.0) 19 (35.8)
7 days post-dose 13 (46.4) 21 (72.4)* 16 (57.1) 19 (67.9)* 19 (70.4)* 23 (41.8)
4 weeks post-dose 21 (77.8)* 22 (78.6)* 20 (74.1)* 18 (64.3) 20 (74.1)* 27 (49.1)
8 weeks post-dose 17 (65.4)* 21 (75.0)* 17 (63.0) 21 (75.0)* 22 (81.5)* 23 (42.6)
SAA       
Baseline 8 (28.6) 9 (32.1) 9 (32.1) 8 (27.6) 9 (33.3) 23 (44.2)
3 days post-dose 15 (57.7) 14 (50.0) 16 (57.1) 13 (46.4) 13 (48.1) 26 (48.1)
7 days post-dose 19 (67.9) 22 (75.9)* 19 (67.9) 21 (75.0)* 17 (65.4) 25 (47.2)
4 weeks post-dose 24 (88.9)* 24 (82.8) 19 (70.4) 20 (71.4) 18 (69.2) 34 (63.0)
8 weeks post-dose 18 (69.2) 21 (80.8) 18 (69.2) 19 (70.4) 20 (74.1) 30 (57.7)
  1. *P < 0.05 vs triamcinolone acetonide 40 mg.
  2. 1Upper limit of normal: 3 mg/L for CRP, 6.7 mg/L for SAA.
  3. CRP, C-reactive protein; SAA, serum amyloid A protein.